Abstract
Repeated hepatectomy is the standard of care for resectable recurrent hepatocellular carcinoma (rHCC) whose recurrence rate remains higher than primary HCC. Moreover, there is no solid perioperative therapy for rHCC. This trial aims to assess the efficacy and safety of neoadjuvant tislelizumab in rHCC patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
